HK1147059A1 - Combination therapy with organic arsenicals - Google Patents
Combination therapy with organic arsenicalsInfo
- Publication number
- HK1147059A1 HK1147059A1 HK11101132.4A HK11101132A HK1147059A1 HK 1147059 A1 HK1147059 A1 HK 1147059A1 HK 11101132 A HK11101132 A HK 11101132A HK 1147059 A1 HK1147059 A1 HK 1147059A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- combination therapy
- organic arsenicals
- arsenicals
- organic
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US157507P | 2007-11-02 | 2007-11-02 | |
| PCT/US2008/012385 WO2009061373A1 (en) | 2007-11-02 | 2008-10-31 | Combination therapy with organic arsenicals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1147059A1 true HK1147059A1 (en) | 2011-07-29 |
Family
ID=40626049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11101132.4A HK1147059A1 (en) | 2007-11-02 | 2011-02-02 | Combination therapy with organic arsenicals |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2394702B1 (en) * | 2005-07-29 | 2014-12-31 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| EP2321012B1 (en) * | 2008-08-20 | 2018-10-10 | Solasia Pharma K.K. | Organoarsenic compounds and methods for the treatment of cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2349729A (en) * | 1940-08-24 | 1944-05-23 | Parke Davis & Co | Therapeutic arsenic preparation |
| US6875451B2 (en) * | 1997-10-15 | 2005-04-05 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
| PL343868A1 (en) | 1997-11-10 | 2001-09-10 | Sloan Kettering Inst Cancer | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
| CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
| EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
| US6191123B1 (en) * | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
| DE60118172T2 (de) * | 2000-04-26 | 2007-03-08 | Oregon Health Sciences University, Portland | Verabreichung von einer chemoschützenden verbindung,welche eine thiolgruppe enthält |
| JP4571408B2 (ja) * | 2002-01-07 | 2010-10-27 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 癌治療薬としての、ｓ−ジメチルアルシノ−チオコハク酸、ｓ−ジメチルアルシノ−２−チオ安息香酸、ｓ−（ジメチルアルシノ）グルタチオン |
| CN1889943A (zh) * | 2003-12-08 | 2007-01-03 | 美国亚利桑那大学董事会 | 协同抗癌组合物 |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| TWI411431B (zh) * | 2004-07-16 | 2013-10-11 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
| EP2394702B1 (en) * | 2005-07-29 | 2014-12-31 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
| TW200829261A (en) * | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
-
2008
- 2008-10-31 KR KR1020107011723A patent/KR20100100835A/ko not_active Application Discontinuation
- 2008-10-31 EP EP08848529A patent/EP2209480B1/en not_active Not-in-force
- 2008-10-31 AU AU2008325243A patent/AU2008325243B2/en not_active Ceased
- 2008-10-31 ES ES08848529T patent/ES2392737T3/es active Active
- 2008-10-31 JP JP2010532063A patent/JP2011502985A/ja active Pending
- 2008-10-31 CA CA2704395A patent/CA2704395A1/en not_active Abandoned
- 2008-10-31 WO PCT/US2008/012385 patent/WO2009061373A1/en active Application Filing
- 2008-10-31 CN CN2008801142801A patent/CN101903029B/zh not_active Expired - Fee Related
- 2008-10-31 US US12/740,661 patent/US8252773B2/en not_active Expired - Fee Related
-
2011
- 2011-02-02 HK HK11101132.4A patent/HK1147059A1/xx not_active IP Right Cessation
-
2012
- 2012-07-26 US US13/559,036 patent/US20120295861A1/en not_active Abandoned
-
2013
- 2013-03-06 US US13/786,591 patent/US20130261082A1/en not_active Abandoned
- 2013-08-09 JP JP2013165982A patent/JP2013227347A/ja not_active Withdrawn
-
2014
- 2014-03-17 JP JP2014053434A patent/JP2014111666A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2704395A1 (en) | 2009-05-14 |
| EP2209480B1 (en) | 2012-09-05 |
| KR20100100835A (ko) | 2010-09-15 |
| AU2008325243A1 (en) | 2009-05-14 |
| ES2392737T3 (es) | 2012-12-13 |
| US20100311689A1 (en) | 2010-12-09 |
| CN101903029B (zh) | 2012-09-26 |
| EP2209480A1 (en) | 2010-07-28 |
| US8252773B2 (en) | 2012-08-28 |
| JP2014111666A (ja) | 2014-06-19 |
| JP2011502985A (ja) | 2011-01-27 |
| US20130261082A1 (en) | 2013-10-03 |
| JP2013227347A (ja) | 2013-11-07 |
| WO2009061373A1 (en) | 2009-05-14 |
| US20120295861A1 (en) | 2012-11-22 |
| EP2209480A4 (en) | 2011-05-11 |
| AU2008325243B2 (en) | 2014-07-03 |
| CN101903029A (zh) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL206654A0 (en) | Combination therapy | |
| GB0712494D0 (en) | Substrate reduction therapy | |
| IL196559A0 (en) | Combination therapy | |
| EP2211620A4 (en) | THERAPEUTIC COMPOUNDS | |
| IL199992A0 (en) | Combination therapy | |
| IL196556A0 (en) | Combination therapy | |
| GB0813087D0 (en) | Therapeutic compounds | |
| GB0716532D0 (en) | Therapeutic compounds | |
| EP2054061A4 (en) | COMBINATION THERAPY | |
| EP2164324A4 (en) | THERAPEUTIC COMPOUNDS | |
| GB0719518D0 (en) | Therapy | |
| ZA201000919B (en) | Antibacterial combination therapy | |
| PL2053582T3 (pl) | Zamknięcie zatrzaskowe | |
| EP2185568A4 (en) | THERAPEUTIC COMPOUNDS | |
| ZA200902203B (en) | Combination therapy | |
| EP2211863A4 (en) | COMBINATION THERAPY | |
| GB0700284D0 (en) | Combination therapy | |
| HK1147059A1 (en) | Combination therapy with organic arsenicals | |
| GB0803948D0 (en) | Combination therapy | |
| GB0702862D0 (en) | Therapeutic compounds | |
| GB0716072D0 (en) | Therapy | |
| GB0700635D0 (en) | Therapy | |
| GB0708188D0 (en) | Therapeutic compounds | |
| GB0705917D0 (en) | Therapy | |
| GB0703963D0 (en) | Therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20161031 |